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Abstract
Socioeconomic inequalities in cancer stage at diagnosis and survival are impor-
tant public health issues. This study investigates the association between socio-
economic position (SEP) and colorectal cancer (CRC) stage at diagnosis and 
survival in Switzerland, a European country with highest level of medical facilities 
and life expectancy. We used population- based CRC data from seven Swiss 
cantonal cancer registries 2001–2008 (N = 10,088) linked to the Swiss National 
Cohort (SNC). Follow- up information was available until the end of 2013. SEP 
was estimated based on education. The association between cancer stage and 
SEP was assessed using logistic regression models including cancer localization 
(colon/rectum), sex, age, civil status, urbanity of residence, language region, 
and nationality (Swiss/non- Swiss). Survival was analyzed using competing risk 
regressions reporting subhazard ratios (SHRs) for the risk of dying due to CRC. 
We observed a social gradient for later stage CRC with adjusted odds ratios 
(ORs) of 1.11 (95% CI: 0.97–1.19) and 1.28 (95% CI: 1.08–1.50) for middle 
and low SEP compared to high SEP. Further, single compared to married people 
had elevated odds of being diagnosed at later stages. Survival was lower in 
patients with CRC with low SEP in the unadjusted model (SHR: 1.18, 95% CI: 
1.07–1.30). After adjustment for stage at diagnosis and further sociodemographic 
characteristics, significant survival inequalities by SEP disappeared but remained 
for non- Swiss compared to Swiss citizens and for patients living in nonurban 
areas compared to their urban counterparts. Swiss public health strategies should 
facilitate equal access to CRC screening and optimal CRC care for all social 
groups and in all regions of Switzerland.
Cancer Medicine
Open Access
2 © 2018 The Authors. <i>Cancer Medicine</i> published by John Wiley & Sons Ltd. 
A. Feller et al.Socioeconomic Position and CRC in Switzerland
Background
In Switzerland, colorectal cancer (CRC) is the third most 
common cancer in men and the second most common 
in women. Approximately 2300 men and 1800 women 
are newly diagnosed with CRC each year [1]. Although 
mortality decreased over the last 30 years, CRC is the 
third most common cause of cancer death among both 
sexes in Switzerland with approximately 900 deaths among 
men and 700 among women [1]. Tumor stage at diagnosis 
is an important prognostics factor, and survival is gener-
ally good for patients with early- stage CRC [2]. Although 
Switzerland has one of the highest survival rate of CRC 
in Europe [3], the 5- year relative survival in Switzerland 
ranges from 12.9% (UICC stage IV) to 93.3% (UICC 
stage I) depending on stage at diagnosis [4]. Therefore, 
early CRC detection is essential to increase treatment 
options and improve outcome. However, most early- stage 
CRCs produce no clinical symptoms and thus are gener-
ally diagnosed in individuals undergoing screening [5, 6].
In Switzerland, health care and preventive services are 
organized at the cantonal level. Up to now, population- 
based organized CRC screening has only been implemented 
in Vaud, one of 26 cantons in Switzerland, starting in 
2015, and offering fecal immunological test or colonoscopy 
to people aged 50–69 years [7]. The canton of Uri main-
tains an organized program since 2000, but the target 
population is not individually invited to attend screening. 
In the remaining cantons, only opportunistic CRC screen-
ing is available, although the benefit of CRC screening 
is well accepted [8, 9].
A negative impact of low socioeconomic position (SEP) 
on cancer stage at diagnosis has been documented for 
several cancer sites including CRC [10–12]. Later stage at 
CRC diagnosis in lower SEP patients might be mediated 
by disparities in healthcare access [13], cancer awareness 
[14], and/or beliefs and attitudes toward cancer and pre-
ventive services such as screening [15]. While CRC screening 
prevalence is generally low in Switzerland (22% in 2012 
in residents aged 50–75 years) [16], persisting socioeco-
nomic inequalities have been reported such that individuals 
with higher SEP use CRC screening more frequently [16, 
17]. Further, screening prevalence by geographic residence 
in Switzerland changed over time with a shift from higher 
(year 2007) to lower (year 2012) screening prevalence in 
the rural compared to the urban population [16, 17].
Worse survival in low SEP patients after CRC diagnosis 
has been observed in several countries [18]. In most stud-
ies [12, 19–21], survival inequalities remained after adjust-
ment for stage at diagnosis and other prognostic factors 
suggesting that additional factors such as quality of care, 
treatment preferences, and/or adherence might have con-
tributed to observed survival discrepancies [12].
Improving health in the whole population requires a 
focus on social equity [22]. However, despite high health 
expenditures, universal health insurance coverage, and one 
of the highest life expectancies in the world [23], there 
is recent evidence of socioeconomic and sociodemographic 
inequalities in cancer detection and survival in Switzerland 
[24]. Up to now, there is no population- based investiga-
tion of this important issue for CRC in Switzerland. 
Therefore, this study aimed to investigate socioeconomic 
and demographic inequalities in CRC stage at diagnosis 
and survival in a Swiss population- based sample of patients 
with CRC diagnosed between 2001 and 2008.
Patients and Methods
Data sources
We used data from the SNC- NICER Cancer Epidemiology 
Study. The SNC- NICER Cancer Epidemiology Study is a 
historical cohort created to investigate sociodemographic 
factors associated with cancer burden in Switzerland. 
Within the framework of the study, the Swiss National 
Cohort (SNC) has been probabilistically linked to incidence 
data of seven Swiss cancer registries (CRs) organized in 
the National Institute for Cancer Epidemiology and 
Registration (NICER) cancer registry network.
An in- depth description of the SNC can be found else-
where [25]. Briefly, census data of 1990 and 2000 were 
probabilistically linked to emigration or cause- specific 
mortality records of the years 1991–2013. The Swiss census 
is mandatory and virtually complete (98.6% in the 2000 
census) [25]. The coding of death certificates and the 
selection of the underlying cause of death are carried out 
by trained staff of the Federal Statistical Office (FSO) for 
the whole country. Since 1995, the 10th revision of the 
International Classification of Diseases and related health 
problems (ICD- 10) has been used for cause of death cod-
ing following international standards. This study used SNC 
sociodemographic information on education level, marital 
status, urbanity of residence, language region of residence, 
nationality, and SNC follow- up information up to the 
end of 2013. The categorization in urban, periurban, and 
rural is based on the spatial classification of communities 
as defined by the Swiss Federal Statistical Office (SFSO). 
The SFSO classifies each community as (1) isolated city, 
(2) main city of an agglomeration, (3) other agglomera-
tion community, and (4) rural community. A detailed 
description can be found elsewhere [26]. For this study, 
isolated cities and main cities of agglomerations have been 
categorized as “urban,” other agglomeration communities 
as “periurban,” and rural communities as “rural”.
Cancer registration in Switzerland is primarily organized 
at the cantonal level. The cantonal CRs record all incident 
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cancer cases diagnosed in their resident population. 
Population- based cancer registration started in Switzerland 
in 1970 and has since been gradually implemented in 23 
of 26 cantons, with full national coverage planned for 
the year 2019. However, some of these CR just started 
recently and were therefore not eligible for this study. A 
detailed description of the history and organization of 
cancer registration in Switzerland can be found elsewhere 
[27].
For the SNC- NICER Cancer Epidemiology Study, all 
CRs implemented before 2008 were invited to participate. 
Seven of 11 CRs eligible for the study provided incidence 
data for the study, starting from the date of Census 1990 
(or earliest year available if later) through the end of 
2008: Fribourg (2006–2008), Geneva (1990–2008), 
Neuchâtel (1990–2008), Ticino (1996–2008), Valais (1990–
2008), Vaud (1990–2008), and Zurich (1990–2008). In 
2008, these cantons represented 46.1% of the Swiss 
population.
Cancer registries cases linked to the SNC included all 
primary cancers diagnosed at or after Census 1990 (or 
earliest year available for CRs implemented after 1990) 
through the end of 2008. Cancer registration information 
comprised sex, date of birth, date of cancer diagnosis, 
basis of diagnosis, topography, morphology, and behavior 
of the tumor (according to the International Classification 
of Diseases for Oncology, third edition (ICD- O- 3)), and 
Tumour, Node and Metastasis staging information (TNM, 
5th or 6th edition).
Study population
The final study population included 10,088 invasive colo-
rectal cancer cases diagnosed between Census 2000 (5 
December 2000) and 31 December 2008. Preceding time 
periods were excluded from analyses due to high propor-
tions of missing stage information (overall >30%, >90% 
for single years in two cantons). People diagnosed at 
85 years of age or older were excluded (N = 1478) because 
of comparably low completeness of stage information 
(72.7%) and data quality (percentage of histologically 
verified cases: 83.9%; death certificate only percentage 
DCO%: 5.4%) in this age- group. Highest completed edu-
cation level was used as a proxy for SEP; hence, people 
under 30 years of age at diagnosis (N = 38) and people 
with missing education information (N = 86) were excluded 
from the study population. The study population showed 
DCO% of 0.8% indicating high completeness of case 
ascertainment. Nearly 98% of the cases were histologically 
verified, and 90.1% had sufficient TNM information to 
classify tumor stage.
To investigate sample representativeness, we compared 
sample characteristics between residents of participating 
cantons and all Switzerland using sociodemographic infor-
mation from the Census 2000 (age, sex, civil status, edu-
cation, urbanity, and language region of residence) (Table 
S1). For the age range included in this study (30–84 years), 
the participating cantons compared to all Switzerland 
showed a slightly different SEP distribution with 24.6% 
and 22.2% classified as high SEP and 48.5% and 51.3% 
classified as middle SEP, respectively. Clear differences in 
the distribution were observed for urbanity of residence, 
language region, and nationality (Table S1).
Statistical methods
Socioeconomic position was classified as low SEP (com-
pulsory education or less), middle SEP (secondary educa-
tion), and high SEP (tertiary education).
For stage calculation, we gave priority to pathological 
T and N over clinical T and N. If clinical and pathologi-
cal M was present, any indication of metastasis was pri-
oritized. Missing M and Mx were categorized as M0.
We calculated UICC stage I- IV depending on the TNM 
edition used for coding (5th and 6th edition). Coding 
changes between the 5th and the 6th edition impacted 
subclassifications (such as IIIa, IIIb.), but not the broader 
categories used within this study.
To assess the association between cancer stage at diag-
nosis and SEP, we used logistic regression models with 
the dependent variable being the dichotomized stage of 
the CRC (UICC stage I vs. more advanced stages) for 
our main analysis, complemented by recalculations using 
alternative cutoffs (stage I- II vs. stage III- IV and stage 
I- III vs. stage IV) The cutoff was chosen based on evi-
dence that individuals with stage I CRC are more likely 
asymptomatic than individuals with stage II- IV CRCs and, 
therefore, are most likely detected through screening [28, 
29]. In addition, the prognostic value of UICC stage is 
limited for intermediate stages (stage II and stage III) 
[2]. The term “later stages” refers to the cutoff stage I 
versus stage II- IV throughout the manuscript if not stated 
otherwise.
We included all variables of interest available in either 
the CR or SNC dataset. We calculated five models using 
the following variables as predictors for CRC stage at 
diagnosis: (model 1) SEP; (model 2) model 1 plus age 
at diagnosis (30–49, 50–64, 65–74, and 75–84 years), civil 
status (single, married, widowed, and divorced), and 
nationality (Swiss and non- Swiss); (model 3) model 2 
plus urbanity (urban, periurban, and rural) and language 
region (German- , French- , and Italian- speaking region); 
(model 4) model 3 plus tumor localization (colon and 
rectum); and (model 5) model 4 plus canton of residence. 
Results were reported as odds ratios (OR) with 95% con-
fidence intervals (95% CI).
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To analyze survival, we performed competing risk regres-
sions based on Fine and Gray’s proportional hazard model 
as main analysis [30]. We used a competing risk approach 
because we were mainly interested in estimating true dif-
ferences in CRC mortality risks (“real world setting”) 
rather than estimating hazard ratios for a hypothetical 
world where competing risks do not exist. However, this 
approach considers both hazards—the hazard due to CRC 
death and the hazard due to other causes of death—con-
jointly. Therefore, we additionally calculated cause- specific 
hazard ratios (CHRs) for CRC death and other causes 
of death using Cox proportional hazard models.
For our main analysis, all underlying causes of death 
other than CRC were classified as competing risks. We 
used six models including the following covariates: (model 
1) SEP; (model 2) model 1 plus age at diagnosis, civil 
status, and nationality; (model 3) model 2 plus urbanity 
and language region of residence; (model 4) model 3 
plus tumor localization; (model 5) model 4 plus UICC 
stage at diagnosis; and (model 6) model 5 plus canton 
of residence. Results were reported as subhazard ratios 
(SHRs) for the risk of dying due to CRC with associated 
95% confidence intervals (95% CI).
The final models have been additionally adjusted for 
canton of residence to account for unmeasured canton 
characteristics associated with SEP and stage and/or sur-
vival. We checked the influence of year of diagnosis in 
preliminary analysis, but observed only marginal changes 
after considering it. Therefore, calendar year has not been 
considered in the final models.
Sensitivity analyses
To assess whether missing stage information biased our 
results, we recalculated all final models after multiple 
imputation of stage at diagnosis with 25 imputations [31]. 
UICC stage was imputed using the following variables as 
predictors: age at diagnosis and follow- up time as con-
tinuous predictors, SEP, sex, civil status, nationality, urban-
ity, language region, tumor localization, and follow- up 
status (alive, death due to CRC, and other causes of death) 
as categorical predictors [32], and an interaction term 
between follow- up time and follow- up status [33].
Results
The contribution of incident CRC cases (Ntotal = 10,088, 
Nstaged = 9147) and person- years (PY) of follow- up 
(PYstotal = 56,657; PYstaged = 52,514) to the final study 
population by CR is presented in Table S2. Overall, around 
30% of the patients with CRC belonged to the low SEP 
group and 50% to the middle SEP group. A summary 
of patient characteristics by SEP is presented in Table 1.
Colorectal cancer stage at diagnosis
Almost two- thirds (65%) of all CRC cases were primarily 
located in the colon and 35% in the rectum (Table 1). 
The majority of all CRC cases were diagnosed at UICC 
stage III (28.1%) or stage II (26.7%). Only 16.5% of all 
cases were detected at stage I. In 9.3% of all cases, stage 
information was missing. The distribution by stage was 
fairly stable over time.
The stage distribution at diagnosis for each analytic 
variable (SEP, further sociodemographic factors and tumor 
localization) is presented in Figure 1.
In the unadjusted model (model 1), we observed a 
social gradient for later stage at diagnosis with ORs of 
1.13 (95% CI: 0.99–1.29) and 1.35 (95% CI: 1.16–1.57) 
for middle and low SEP patients compared to high SEP 
patients, respectively (Table 2). After adjustment for further 
demographic factors, tumor localization, and canton of 
residence (model 5), socioeconomic inequalities slightly 
decreased to 1.11 (95% CI: 0.97–1.27) for middle SEP 
and to 1.28 (95% CI: 1.08–1.50) for low SEP. However, 
we observed no social gradients for the alternative cutoffs 
contrasting stage I- II versus stage III- IV (Table S3) and 
stage I- III versus stage IV (Table S4).
Concerning civil status, we observed an increased risk 
of later stage at CRC diagnosis for single compared to 
married patients (OR 1.36, 95% CI: 1.10–1.67), but not 
for widowed or divorced ones. Further, rectal cancer was 
less likely to be diagnosed at later stage compared to 
colon cancer (OR 0.68, 95% CI: 0.61–0.76).
Colorectal cancer survival
Of the 10,088 patients with CRC, 3515 died before the 
end of follow- up (34.8%) and 43 patients (0.4%) were 
lost to follow- up (Table 1).
Patients with CRC with low SEP were more likely to 
die of their disease compared to patients with CRC with 
high SEP in the unadjusted model (SHR 1.18, 95% CI: 
1.07–1.30) (Table 3, model 1). After adjustment for further 
demographic characteristics, relative mortality risk of low 
SEP patients shrank to SHR 1.14 (95% CI: 1.02–1.27) 
(model 3) and declined further to SHR 1.08 (95% CI: 
0.96–1.21) (model 6) after additional adjustment for stage 
at diagnosis, tumor localization, and canton of residence. 
Later stage at diagnosis was strongly associated with an 
increased risk of CRC death (stage II: SHR 3.20, 95% 
CI: 2.54–4.02; stage III: SHR 8.13, 95% CI: 6.54–10.10; 
stage IV: SHR 30.00, 95% CI: 24.15–27.21 compared with 
patients diagnosed with stage I CRCs). Further, patients 
with rectal cancer compared with patients with colon 
cancer (SHR 1.10, 95% CI: 1.01–1.19), patients with for-
eign nationality compared with Swiss citizens (SHR 1.20, 
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95% CI: 1.08–1.34), and patients living in a periurban 
(SHR 1.15, 95% CI: 1.05–1.25) or rural area (SHR 1.15, 
95% CI: 1.02–1.30) compared with patients living in urban 
areas showed an elevated risk of CRC death in the fully 
adjusted model. Patients diagnosed below the age of 
50 years showed the most favorable survival (SHR 0.69, 
95% CI: 0.58–0.82), followed by patients aged 50–64 years 
(reference group) and patients aged 65–74 years (SHR 
1.17, 95% CI: 1.07–1.29). Worst survival was observed 
for patients aged 75–84 years at diagnosis, the oldest age- 
group included in this study, with a SHR of 1.68 (95% 
CI: 1.51–1.85) compared with patients diagnosed at age 
50–64 years).
Cause- specific hazard ratios of CRC death and other 
causes of death in patients diagnosed with CRC are pre-
sented in Table S5. The factors found to have significant 
association with CRC death were identical in both 
approaches with similar effect sizes in both final 
models.
Sensitivity analyses
Stage at presentation and survival analyses after multiple 
imputation of stage information are presented in Tables 
S6 and S7, respectively. The multiple imputation approach 
showed similar results compared to our main analyses 
using listwise deletion (complete case analyses) to handle 
missing stage information. Overall, there is no evidence 
for biased estimates or insufficient precision due to our 
approach using listwise deletion.
Discussion
Summary of main findings
Our study provides evidence for socioeconomic inequali-
ties in CRC stage at diagnosis and subsequent survival 
in Switzerland. Differences in survival were mainly driven 
by inequalities in stage at diagnosis rather than stage- 
specific survival inequalities. Compared with Swiss nationals 
and urban residents, foreign residents and those living in 
urban or periurban areas had poorer prognosis, even after 
adjustment for stage at diagnosis, SEP, and further soci-
odemographic characteristics.
Discussion in the context of the literature
Studies conducted in other developed countries have 
reported socioeconomic inequalities in CRC stage at diag-
nosis [10–12] and survival [11, 18–20]. However, social 
disparities were not observed for all regions or countries 
and for all time periods investigated [34, 35]. A study 
based on Surveillance, Epidemiology and End Results 
(SEER) data 1973–2001, for example, reported socioeco-
nomic stage disparities for breast and prostate cancer, 
but not for CRC [35]. In another population- based study 
conducted in Portugal, socioeconomic inequalities in CRC 
survival disappeared after accounting for differences in 
background mortality [34]. In our study, socioeconomic 
inequalities in stage at diagnosis appeared to be the main 
determinant of inequalities in CRC survival.
Inequalities in stage at diagnosis across social groups 
are usually explained by disparities in healthcare access 
[13], cancer awareness [14], and/or beliefs and attitudes 
toward cancer and preventive services such as screening 
[15]. However, the importance of each of these factors 
can be expected to vary by country/region and healthcare 
system. Disparities in healthcare access, for example, might 
be of lesser importance in countries with national health 
insurance compared to countries with strictly voluntary 
or private health insurance. Therefore, underlying mecha-
nisms for these social inequalities have to be investigated 
on a national or regional basis.
In our study, socioeconomic inequalities in stage at 
diagnosis decreased after adjustment for further demo-
graphic characteristics, but did not fully disappear. In 
addition, a social gradient was only observed for the main 
cutoff contrasting stage I versus stage II- stage IV, but not 
for the alternative cutoffs. In the descriptive analysis, stage 
differences between SEP groups appeared rather small and 
were most pronounced for stage I and stage II CRCs, 
whereas proportions of stage III and metastatic CRC were 
similar across SEP groups. Early- stage CRCs are generally 
asymptomatic and mainly diagnosed through screening 
[5, 6]. Therefore, observed disparities in stage at diagnosis 
might be best explained by differences in screening activi-
ties. Two recent Swiss studies showed that individuals of 
lower SEP were less likely to undergo CRC screening [16, 
17]. In 2012, for example, CRC screening utilization in 
Switzerland in individuals aged 50–75 years was 28.6% 
and 16.0% for people in the highest and lowest income 
quintile, respectively [16].
For the time period under investigation, no organized 
population- based CRC screening program existed in 
Switzerland. Whereas organized screening programs are 
now widespread in Europe [36, 37], only one canton in 
Switzerland has to date implemented a population- based 
CRC screening program. Despite universal health insur-
ance in Switzerland, CRC screening was not free in the 
time period under investigation. Only since July 2013, 
two methods of CRC screening (fecal occult blood test 
and colonoscopy) have been added to basic health cover-
age. But importantly, CRC screening has not been exempted 
from the franchise and the deductible. Reimbursement 
regardless of franchise is currently only guaranteed in the 
cantons of Vaud and Uri covering around 10% of the 
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Swiss population. Therefore, the majority of individuals 
with only basic health insurance have still to cover the 
full costs in case the annual franchise (300–2500 CHF) 
is not met (or up to 10% of the costs as a deductible 
if the annual upper limit of 700 CHF has not been 
reached).
We observed a significant increased risk of later stage 
CRC at diagnosis for single compared to married patients. 
An impact of marital status on cancer stage at diagnosis, 
treatment, and/or survival has been reported in other 
studies [24, 38–40]. A SEER study, for example, found 
that unmarried compared to married patients were at 
higher risk of being diagnosed with metastatic cancer, 
undertreatment, and cancer death, suggesting that decreased 
social support may negatively influence cancer detection, 
treatment uptake, and survival [38]. However, in our 
study, an increased risk of being diagnosed at later stages 
was only seen in single patients. This was reflected by 
the lower overall survival of single compared to married 
patients. After stage adjustment, observed survival 
Table 1. Characteristics of patients with colorectal cancer by socioeconomic position (SEP).
Analysis of SEP and 
stage at diagnosis
Low SEP Middle SEP High SEP Total
N Column % N Column % N Column % N Column %
Sex
Male 1215 40.9 2892 57.6 1593 76.0 5700 56.5
Female 1757 59.1 2127 42.4 504 24.0 4388 43.4
Age at diagnosis
<50 years 135 4.5 361 7.2 172 8.2 668 6.6
50–64 years 672 22.6 1570 31.3 765 36.5 3007 29.8
65–74 years 890 30.0 1617 32.2 673 32.1 3180 31.5
75–84 years 1275 42.9 1471 29.3 487 23.2 3233 32.0
Civil status
Single 259 8.7 453 9.0 213 10.2 925 9.2
Married 1851 62.3 3404 67.8 1523 72.6 6778 67.2
Widowed 617 20.8 619 12.3 132 6.3 1368 13.6
Divorced 245 8.2 543 10.8 229 10.9 1017 10.1
Urbanity of residence
Urban 1109 37.3 1728 34.4 693 33.1 3530 35.0
Periurban 1271 42.8 2604 51.9 1182 56.4 5057 50.1
Rural 592 19.9 687 13.7 222 10.6 1501 14.9
Language region of residence*
German- speaking 
region
940 31.6 2288 45.6 852 40.6 4080 40.4
French- speaking 
region
1571 52.9 2120 42.2 1034 49.3 4725 46.8
Italian- speaking 
region
461 15.5 611 12.2 211 10.1 1283 12.7
Nationality
Swiss 2183 73.5 4383 87.3 1757 83.8 8323 82.5
Non- Swiss 789 26.6 636 12.7 340 16.2 1765 17.5
Localization of the cancer
Colon 1971 66.3 3260 65.0 1344 64.1 6575 65.2
Rectum 1001 33.7 1759 35.1 753 35.9 3513 34.8
Stage at diagnosis (UICC stage)
Stage I 434 14.6 847 16.9 385 18.4 1666 16.5
Stage II 827 27.8 1347 26.8 521 24.9 2695 26.7
Stage III 868 29.2 1383 27.6 582 27.8 2833 28.1
Stage IV 564 19.0 991 19.7 398 19.0 1953 19.4
Unknown stage 279 9.4 451 9.0 211 10.1 941 9.3
Vital status at end of follow- up
Alive 1794 60.4 3288 65.5 1448 69.1 6530 64.7
Dead 1152 38.8 1718 34.2 645 30.8 3515 34.8
Lost to follow- up 26 0.9 13 0.3 4 0.2 43 0.4
Total N row % 2972 29.5 5019 49.8 2097 20.8 10,088 100.0
*German- speaking region: eastern parts of the canton of Fribourg, eastern parts of the canton of Valais (upper Valais), and canton of Zurich; French- 
speaking region: western parts of the canton of Fribourg, canton of Geneva, canton of Neuchâtel, western parts of the canton of Valais (Central and 
Lower Valais), and canton of Vaud; Italian- speaking region: canton of Ticino.
7© 2018 The Authors. <i>Cancer Medicine</i> published by John Wiley & Sons Ltd. 
Socioeconomic Position and CRC in SwitzerlandA. Feller et al.
disparities did not persist, suggesting that treatment uptake 
and quality of care did not depend on civil status.
Looking at the age at diagnosis, patients with CRC 
below the age of 50 years had the most favorable overall 
and stage- adjusted survival, although they had the highest 
proportion of stage III and stage IV cancers. Better or 
equal prognosis of younger than older patients, even when 
presenting at later stages and with more aggressive tumors, 
has been previously reported [41–43].
The survival advantage of younger patients might be 
associated with less comorbidities, more aggressive treat-
ment, better treatment adherence, and/or less treatment- 
associated complications. Notably, there is also evidence 
from the United States that young patients with colon 
Figure 1. Distribution of colorectal cancer stage at diagnosis by sociodemographic characteristics and tumor localization (N = 9147). The analysis has 
been restricted to cases with known stage at diagnosis (9147 of 10,088 cases).
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cancer are overtreated and at an increased risk to receive 
unnecessary chemotherapy [44]. For older patients, an 
opposite trend has been reported suggesting that older 
patients with CRC (>75 years) are often undertreated 
[45]. The oldest patients included in our study (75–
84 years) clearly experienced the poorest survival. Further 
investigations are needed to disentangle the impact of 
patient- , tumor- , and treatment- related factors on age- 
specific outcomes in Swiss patients with CRC.
Patients living in periurban and rural areas showed 
lower stage- adjusted survival compared with their urban 
counterparts. Some studies from other countries reported 
similar results for patients with CRC [46, 47], but other 
studies found the opposite result [48]. Although Switzerland 
has a high hospital density [23], inhabitants of remote 
regions, peripheral valleys, or mountainous areas may have 
long travel distances for care. Travel burden has been 
found to influence the choice of treatment and treatment 
site, to lower treatment adherence and to worsen prognosis 
[49, 50]. There is also convincing evidence that quality 
of CRC surgery depends on hospital volume and surgeon’s 
clinical experience [51, 52]. Therefore, observed survival 
disparities for CRC might be at least partly explained by 
differences in quality of care, assuming that patients with 
cancer living in rural areas are treated more frequently 
at low- volume hospitals located closest to their home [50].
Compared to Swiss nationals, survival of non- Swiss 
patients with CRC was poorer, even after adjustment for 
stage at diagnosis, SEP, and further sociodemographic 
characteristics. Interestingly, patients’ nationality had no 
impact on CRC stage at diagnosis, suggesting equal access 
to screening and diagnostic procedures. The difference in 
CRC survival between Swiss and foreigners might be due 
to adherence to treatment, delay in treatment, or other 
Table 2. Odds ratios (OR) of later colorectal cancer stage at diagnosis (stage I vs. stage II–IV).
Model 1 Model 2 Model 3 Model 4 Model 5*
OR [95% CI] OR [95% CI] OR [95% CI] OR [95% CI] OR [95% CI]
SEP
High SEP (ref.)
Middle SEP 1.13 [0.99–1.29] 1.11 [0.97–1.27] 1.11 [0.97–1.27] 1.12 [0.97–1.28] 1.11 [0.97–1.27]
Low SEP 1.35 [1.16–1.57] 1.28 [1.09–1.50] 1.27 [1.08–1.50] 1.29 [1.09–1.51] 1.28 [1.08–1.50]
Sex
Male (ref.)
Female 1.08 [0.96–1.21] 1.08 [0.96–1.21] 1.05 [0.93–1.18] 1.05 [0.93–1.18]
Age at diagnosis
50–64 years (ref.)
<50 years 1.22 [0.96–1.54] 1.22 [0.96–1.55] 1.22 [0.96–1.54] 1.22 [0.96–1.54]
65–74 years 1.03 [0.90–1.18] 1.03 [0.91–1.18] 1.02 [0.89–1.16] 1.02 [0.89–1.16]
75–84 years 1.20 [1.04–1.38] 1.19 [1.03–1.38] 1.14 [0.98–1.31] 1.14 [0.99–1.32]
Civil status
Married (ref.)
Single 1.36 [1.11–1.68] 1.35 [1.10–1.66] 1.35 [1.10–1.67] 1.36 [1.10–1.67]
Widowed 1.05 [0.88–1.25] 1.04 [0.87–1.25] 1.05 [0.88–1.25] 1.05 [0.88–1.25]
Divorced 1.16 [0.97–1.39] 1.15 [0.96–1.38] 1.15 [0.96–1.38] 1.15 [0.96–1.38]
Nationality
Swiss (ref.)
Non- Swiss 1.02 [0.88–1.18] 1.02 [0.88–1.18] 1.02 [0.88–1.18] 1.03 [0.88–1.19]
Urbanity
Urban (ref.)
Periurban 0.92 [0.82–1.04] 0.92 [0.82–1.04] 0.93 [0.82–1.04]
Rural 0.98 [0.82–1.16] 0.97 [0.81–1.15] 0.96 [0.80–1.15]
Language region†
German (ref.)
French 1.04 [0.93–1.17] 1.04 [0.92–1.17] 1.19 [0.84–1.69]
Italian 0.95 [0.81–1.13] 0.93 [0.79–1.10] 0.93 [0.78–1.10]
Localization
Colon (ref.)
Rectum 0.68 [0.61–0.76] 0.68 [0.61–0.76]
*Additionally adjusted for canton of residence to account for unmeasured canton characteristics associated with SEP and stage.
†German- speaking region: eastern parts of the canton of Fribourg, eastern parts of the canton of Valais (upper Valais), and canton of Zurich; French- 
speaking region: western parts of the canton of Fribourg, canton of Geneva, canton of Neuchâtel, western parts of the canton of Valais (Central and 
Lower Valais), and canton of Vaud; Italian- speaking region: canton of Ticino.
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unmeasured factors and warrants further studies. The 
non- Swiss population is composed of highly heterogeneous 
groups according to the country of origin, migration status 
(first- , second- , or third- generation immigrants), type of 
residence permit, income, employment, and knowledge 
of one of the Swiss national languages, to name a few. 
Further investigations of this issue should pay particular 
attention to the broad diversity of immigrants and 
foreigners living in Switzerland. This is especially important 
as there is a lack of information about migrants’ health 
and health needs in Switzerland.
Finally, as observed in other studies, patients with rectal 
cancer compared with patients with colon cancer showed 
a reduced risk of being diagnosed at later stages [19, 20]. 
This pattern by anatomic site might reflect the effect of 
screening which is more effective for distal than proximal 
Table 3. Subhazard ratios and 95% confidence intervals (95% CI), risk of colorectal cancer death in patients with colorectal cancer.
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6*
SHR [95% CI] SHR [95% CI] SHR [95% CI] SHR [95% CI] SHR [95% CI] SHR [95% CI]
SEP
High SEP (ref.)
Middle SEP 1.07 
[0.98–1.17]
1.05 [0.96–1.16] 1.05 [0.95–1.15] 1.05 [0.95–1.15] 0.99 [0.90–1.10] 0.99 [0.89–1.09]
Low SEP 1.18 
[1.07–1.30]
1.14 [1.02–1.27] 1.14 [1.02–1.27] 1.13 [1.02–1.26] 1.09 [0.97–1.22] 1.08 [0.96–1.21]
Sex
Male (ref.)
Female 0.96 [0.88–1.03] 0.96 [0.89–1.04] 0.96 [0.89–1.04] 0.95 [0.88–1.03] 0.95 [0.88–1.04]
Age at diagnosis
50–64 years (ref.)
<50 years 0.80 [0.68–0.95] 0.80 [0.68–0.94] 0.80 [0.68–0.95] 0.69 [0.59–0.83] 0.69 [0.58–0.82]
65–74 years 1.11 [1.01–1.21] 1.11 [1.02–1.22] 1.11 [1.02–1.22] 1.18 [1.07–1.29] 1.17 [1.07–1.29]
75–84 years 1.48 [1.35–1.62] 1.49 [1.36–1.64] 1.49 [1.36–1.64] 1.67 [1.51–1.85] 1.68 [1.51–1.85]
Civil status
Married (ref.)
Single 1.14 [1.00–1.29] 1.15 [1.01–1.31] 1.14 [1.01–1.30] 0.97 [0.85–1.12] 0.99 [0.86–1.14]
Widowed 0.89 [0.79–1.00] 0.89 [0.79–1.00] 0.89 [0.79–1.00] 0.95 [0.83–1.08] 0.95 [0.84–1.08]
Divorced 1.10 [0.98–1.24] 1.11 [0.99–1.25] 1.10 [0.98–1.24] 1.00 [0.88–1.13] 1.02 [0.90–1.15]
Nationality
Swiss (ref.)
Non- Swiss 1.15 [1.04–1.27] 1.13 [1.02–1.25] 1.13 [1.02–1.25] 1.22 [1.10–1.36] 1.20 [1.08–1.34]
Urbanity
Urban (ref.)
Periurban 1.08 [1.00–1.17] 1.07 [1.00–1.17] 1.13 [1.04–1.23] 1.15 [1.05–1.25]
Rural 1.16 [1.04–1.29] 1.15 [1.04–1.29] 1.15 [1.03–1.30] 1.15 [1.02–1.30]
Language region†
German (ref.)
French 0.95 [0.88–1.03] 0.95 [0.88–1.03] 0.93 [0.85–1.01] 0.97 [0.77–1.23]
Italian 0.93 [0.83–1.04] 0.93 [0.83–1.04] 0.90 [0.80–1.02] 0.91 [0.81–1.03]
Localization
Colon (ref.)
Rectum 1.01 [0.941.09] 1.10 [1.01–1.19] 1.10 [1.01–1.19]
Stage at diagnosis
Stage I (ref.)
Stage II 3.20 [2.55–4.02] 3.20 [2.54–4.02]
Stage III 8.11 [6.53–10.08] 8.13 [6.54–10.10
Stage IV 29.83 [24.03–37.03] 30.00 [24.15–37.21]
Survival was analyzed using competing risk regressions based on Fine and Gray’s proportional hazard model. All underlying causes of death other 
than colorectal cancer (CRC) were classified as competing risks. Results are reported as subhazard ratios for risk of dying due to CRC (SHRs) with 95% 
confidence intervals (95% CI).
*Additionally adjusted for canton of residence to account for unmeasured canton characteristics associated with SEP and stage and/or survival. 
†German- speaking region: eastern parts of the canton of Fribourg, eastern parts of the canton of Valais (upper Valais), and canton of Zurich; French- 
speaking region: western parts of the canton of Fribourg, canton of Geneva, canton of Neuchâtel, western parts of the canton of Valais (Central and 
Lower Valais), and canton of Vaud; Italian- speaking region: canton of Ticino.
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subsites [9]. Stage- adjusted survival was lower in patients 
with rectal cancer than colon cancer, which might be 
related to etiological differences and differences in treat-
ment response [53].
Strengths and limitations
This study is the first population- based Swiss study inves-
tigating socioeconomic inequalities in CRC stage at diagnosis 
and subsequent survival. With the exception of the Geneva 
CR, information on education and other SEP indicators 
is not systematically collected by other Swiss CRs. The 
dataset of the SNC- NICER Cancer Epidemiology Study 
opened the opportunity, for the first time, to investigate 
this topic using data from multiple Swiss cantons.
The seven participating CRs covered approximately 50% 
of the Swiss population. The covered population was not 
representative of the Swiss population with regard to SEP, 
nationality, urbanity, and language region of residence. 
Therefore, generalizability of these findings is limited.
Our study has some limitations. First, SEP is a mul-
tidimensional construct and highest completed education 
level, which has been used as proxy for SEP in our study, 
does not fully capture it. However, education forms a 
unique dimension of SEP, with qualities that make it 
especially important to health [54]. Further, education 
precedes and influences other dimensions of SEP, such 
as occupational status and personal income [54]. In addi-
tion, there is considerable international evidence that 
education is strongly associated with health, health behav-
ior, and preventive service use and that a substantial share 
of these effects is of causal origin [55]. In addition, edu-
cation is fairly stable after early adulthood and virtually 
complete in the study population (>99%).
Another drawback of the study is the lack of more 
detailed tumor characteristics (besides TNM stage) and 
other prognostic factors, such as comorbidities and CRC 
treatment. TNM stage is the most important single pre-
dictor for CRC survival. However, TNM stage information 
of CRC provides the strongest prognostic information for 
patients with early or advanced disease, but is of limited 
value for intermediate stages [2]. For example, survival 
of stage IIB tumors is lower than that of some stage III 
CRCs. Therefore, Doubeni et al. [56], for example, defined 
late stage as stage IIB- IV CRCs. Due to the lack of his-
topathologic subtype information, this was not feasible 
in our study, but calculations have been redone using 
alternative cutoffs (I- II vs. III- IV and I- III vs. IV). Overall, 
the knowledge of additional prognostic tumor character-
istics such as histopathologic subtype, grade, lymphatic 
invasion, venous invasion, or perineural invasion [2] would 
have particularly improved our risk adjustment for patients 
diagnosed with intermediate stages.
In patients with CRC, comorbidities are common, par-
ticularly in older males [57, 58] with low SEP [57]. 
Comorbidities have an adverse effect on overall and stage- 
specific CRC survival [59, 60]. Furthermore, patients with 
comorbidities are less likely to receive standard therapy 
and to complete treatment courses as intended [59]. 
However, whether these treatment disparities reflect appro-
priate treatment decisions of the treating physicians, patient 
preferences, poorer treatment adherence of the patients, 
or inequalities in cancer care remains unclear [59] and 
needs individual investigations by country/region and 
healthcare system. Unfortunately, comorbidity status of 
the patients was not available for this study. In addition, 
no individual data concerning CRC screening history was 
available for this study.
In addition, misclassification of cause of death might 
have biased survival estimates [61]. Therefore, performing 
relative survival would have been beneficial, also in respect 
of potential counfounding by comorbidity status (see 
above). However, due to the lack of adequate life tables 
(e.g., life stables stratified by socioeconomic position.), 
this was not feasible within this study.
Finally, sociodemographic characteristics (except age at 
diagnosis) were obtained from the census. With increasing 
time between date of census and end of follow- up, char-
acteristics such as marital status or place of residence 
might have changed resulting in misclassification when 
referring to the time of or after CRC diagnosis.
Conclusions
In Switzerland, the majority of patients with CRC are 
still diagnosed at a late stage, and the likelihood to have 
a late- stage CRC is highest in people of low SEP. These 
findings highlight the need to increase screening prevalence 
and awareness of the benefits of CRC screening in all 
social groups. As the net benefit of CRC screening is well 
documented, the implementation of organized population- 
based CRC screening programs in all cantons of Switzerland 
should be a priority of Swiss healthcare policies. Further, 
exempting CRC screening from the franchise and the 
deductible of the basic health insurance might help to 
especially increase the screening prevalence in the popula-
tion with lower SEP.
Survival inequalities by SEP could be sufficiently 
explained by differences in stage at diagnosis, arguing 
against substantial socioeconomic inequalities in CRC 
treatment. But importantly, non- Swiss compared to Swiss 
citizens and patients living in nonurban areas compared 
to their urban counterparts showed poorer survival even 
in the fully adjusted model, suggesting that differences 
in treatment adherence or quality of care might play a 
role. Reasons underpinning these inequalities, however, 
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warrant further investigations in order to identify factors 
that can be addressed to improve outcomes equally in 
all social groups.
Overall, it is alarming that these social inequalities have 
been observed in Switzerland, a wealthy country with 
universal health insurance coverage and one of the highest 
life expectancies in the world. Swiss public health strate-
gies should facilitate equal access to CRC screening and 
optimal CRC care for all social groups and in all regions 
of Switzerland.
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